Analyse Anavex Life Sciences Corp. (AVXL) — Kairos Score 52/100

À propos de Anavex Life Sciences Corp.

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, as well as exhibits anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71 that targets SIGMAR1 and M1 muscarinic receptors, which is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, such as cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.

Informations clés

🕴️ Activité des initiés (90 jours)

0 transactions — 0 achats et 0 ventes déclarés par les dirigeants de Anavex Life Sciences Corp..

🏦 Hedge Funds

16 fonds institutionnels déclarent une position sur AVXL dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur AVXL.

• Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies
• Anavex Receives FDA IND Clearance for Blarcamesine in Fragile X Syndrome, Enabling Phase 2a Trial

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.